title: The role of prostaglandin E2 in renal cell cancer development: future implications for prognosis and therapy.
abstract: COX-2 plays a crucial pathophysiological role in the development of renal cell cancer (RCC). Recently, it has been shown that COX-2 inhibition enhances the efficacy of immunotherapy and tyrosine kinase inhibitor-based treatment. At the same time, molecular analyses revealed particular contribution of a COX-2 product - prostaglandin E2 (PGE2) - in RCC development. PGE2 was shown to activate Akt/RGC2/RalA signaling cascade in RCC cells. It also demonstrated upregulation of the expression of HIF-1α and PI3K/Akt/mTOR signaling pathway. All together, these data suggest that targeted anti-PGE2 therapies may offer an interesting therapeutic option for RCC patients in the future.
authors.affiliation: Department of Oncology with Laboratory of Molecular Oncology, Military Institute of Medicine, Szaserow 128, 04-141 Warsaw, Poland.
authors.forename: Katarzyna
authors.initials: K
authors.lastname: Kaminska
authors.forename: Cezary
authors.initials: C
authors.lastname: Szczylik
authors.forename: Fei
authors.initials: F
authors.lastname: Lian
authors.forename: Anna M
authors.initials: AM
authors.lastname: Czarnecka
mesh_terms: D000818:Animals; D002292:Carcinoma, Renal Cell / Q000175:diagnosis / Q000378:metabolism* / Q000628:therapy; D002471:Cell Transformation, Neoplastic / Q000378:metabolism*; D051546:Cyclooxygenase 2 / Q000378:metabolism; D015232:Dinoprostone / Q000378:metabolism*; D006801:Humans; D007680:Kidney Neoplasms / Q000175:diagnosis / Q000378:metabolism* / Q000628:therapy; D011379:Prognosis; D018078:Receptors, Prostaglandin E / Q000378:metabolism; D015398:Signal Transduction
chemical_list: D018078:Receptors, Prostaglandin E; D051546:Cyclooxygenase 2; D015232:Dinoprostone
keywords: COX-2; NSAID; PGE-2; celecoxib; cyclooxygenase-2; interferon; prostaglandin; renal cell carcinoma; sunitinib